Indianapolis, INNCT06922591Now EnrollingIRB Ready

Pancreatic Cancer Clinical Trial in Indianapolis, IN

Access cutting-edge pancreatic cancer treatment through this phase 1/2 clinical trial at a research site in Indianapolis. Study-provided care at no cost to qualified participants.

Sponsored by Tango Therapeutics, Inc.

Quick Self-Assessment

See if you qualify for this Indianapolis location

Preparing your pre-screening questions…

Expert Care in Indianapolis

Access pancreatic cancer specialists at no cost

IRB Approved

This study follows strict safety protocols and ethical guidelines

No-Cost Care

All study-related pancreatic cancer treatment provided free

Apply for This Indianapolis Location

Check if you qualify for this pancreatic cancer clinical trial in Indianapolis, IN

Secure & Confidential

Your information is protected and will only be shared with the research team.

Why Participate?

  • No-Cost Study Care

  • Local to Indianapolis

    Convenient for IN residents

  • Cutting-Edge Treatment

    Access to innovative therapies

  • Expert Medical Care

    Close monitoring by specialists

  • Possible Compensation*

    For time and travel

*Compensation varies by study. Confirm details with coordinator.

Simple Process

  1. 1Submit this form
  2. 2Phone screening
  3. 3Visit Indianapolis site if eligible
  4. 4Begin participation

About This Pancreatic Cancer Study in Indianapolis

TNG462-C102 is a Phase 1/2, open-label, multicenter study designed to determine the safety, tolerability, PK, PD, and preliminary antineoplastic activity of oral TNG462 in combination with RMC-6236 or RMC-9805. The study comprises a dose escalation phase and a dose expansion phase.

Sponsor: Tango Therapeutics, Inc.

Who Can Participate

Inclusion Criteria

Is ≥18 years of age at the time of signature of the main study ICF.
Has an ECOG PS of 0 or 1.
Has a tumor with loss of MTAP protein or bi-allelic deletion of the MTAP gene
Arms A and B only: Has a tumor with a RAS mutation
Pathologically documented metastatic PDAC or locally advanced, recurrent or metastatic NSCLC
Has received prior standard therapy
Arms A and B only: Must not have received prior RAS-targeted therapy
Has evidence of measurable disease based on RECIST v1.1.
Adequate organ function
Must be able to swallow tablets.
Negative pregnancy test at screening
Written informed consent must be obtained according to local guidelines

Exclusion Criteria

Has received prior treatment with a PRMT5 inhibitor, or MAT2A inhibitor
Arms A and B only: Prior enrollment in any phase 3 clinical trial of RMC-6236 or RMC-9805
Known allergy, hypersensitivity or intolerance to TNG462 (all arms), RMC-6236 Arm A), RMC-9805 (Arm B), mFOLFIRINOX (Arm C), gemcitabine/nab-paclitaxel (Arm D) or their excipients
Has uncontrolled intercurrent illness that will limit compliance with the study requirements.
Has an active infection requiring systemic therapy.
Is currently participating in or has planned concurrent participation in a study of another investigational agent or device.
Has impairment of GI function or disease that may significantly alter the absorption of the oral medications
Has known or suspected active or untreated CNS metastases associated with progressive neurological symptoms
Has current active liver disease from any cause
Is known to be HIV positive, unless all the following criteria are met:
CD4+ count ≥300/µL.
Undetectable viral load.
Receiving highly active antiretroviral therapy
Has clinically relevant cardiovascular disease
History of or presence of active interstitial lung disease
Is a female patient who is pregnant or lactating
Is unwilling or unable to comply with the scheduled visits, study treatment administration plan, laboratory tests or other study procedures and study restrictions.
Has a prior or ongoing clinically significant illness, medical condition, surgical history, physical finding, or laboratory abnormality that, in the investigator's opinion may affect the safety of the patient or impair the ability to assess study results

Not sure if you qualify? Submit your interest and a study coordinator will help determine your eligibility.

Frequently Asked Questions

Q:Is this study available in Indianapolis?

Yes, this clinical trial (NCT06922591) has an active research site in Indianapolis, IN that is currently enrolling participants.

Q:Is it safe to participate?

Clinical trials follow strict safety guidelines and ethical standards. This study has been reviewed and approved, and participants are closely monitored by medical professionals. You can withdraw at any time.

Q:Will I be compensated?

Many clinical trials offer compensation for your time and travel expenses. Specific compensation details will be discussed during the screening process. All study-related medical care is provided at no cost.

Q:Can I leave the trial if I change my mind?

Absolutely. Participation is completely voluntary. You have the right to withdraw from the study at any time, for any reason, without penalty.

Still have questions? Our study coordinators are here to help.

Pancreatic Cancer Treatment Options in Indianapolis, IN

If you're searching for pancreatic cancer treatment options in Indianapolis, IN, this clinical trial (NCT06922591) may be an excellent opportunity. Clinical trials provide access to cutting-edge treatments that aren't yet available to the general public, often at no cost to participants.

Our Indianapolis research site is actively enrolling participants for this phase 1/2 clinical trial. You'll receive care from experienced pancreatic cancer specialists who are at the forefront of medical research. All study-related care, including examinations, treatments, and monitoring, is provided at no cost to qualified participants.

Looking for more options? Browse all pancreatic cancer clinical trials near you to find additional studies recruiting in your area.

More Pancreatic Cancer Trials in Indianapolis, IN

See all pancreatic cancer clinical trials recruiting in Indianapolis — not just this study.

Browse Pancreatic Cancer Trials in Indianapolis →

Browse More Trials by Condition

Pancreatic Cancer TrialsInterstitial Cystitis TrialsAll Conditions →

Ready to Join in Indianapolis?

Take the first step toward participating in this groundbreaking clinical trial

Secure · Expert Care · Indianapolis, IN